MARKET

AXGN

AXGN

Axogen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.00
+0.48
+5.04%
After Hours: 10.15 +0.15 +1.50% 17:02 05/20 EDT
OPEN
9.68
PREV CLOSE
9.52
HIGH
10.06
LOW
9.48
VOLUME
294.41K
TURNOVER
0
52 WEEK HIGH
22.82
52 WEEK LOW
6.87
MARKET CAP
419.81M
P/E (TTM)
-13.0548
1D
5D
1M
3M
1Y
5Y
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
ALACHUA, Fla. and TAMPA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO, and pre...
GlobeNewswire · 2d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades
Benzinga · 05/09 14:07
--Canaccord Genuity Upgrades AxoGen to Buy from Hold, Adjusts Price Target to $15 from $10
MT Newswires · 05/09 12:18
Mid-Day Market Update: U.S. Stocks Extend Losses; Dow Dips Over 1,100 Points
U.S. stocks extended losses midway through trading, with the Dow Jones dipping more than 1,100 points on Thursday.
Benzinga · 05/05 16:08
Axogen Aces Phase 3 Study For Avance Nerve Graft
Benzinga · 05/05 14:58
AxoGen, Better Therapeutics top healthcare gainers; Nephros, BioAtla lead losers' pack
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX)  +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCAB) -27%. Outset Medical (OM) -10%. Signify Health (SGFY) -...
Seekingalpha · 05/05 14:02
Axogen stock rises 9% after Q1 revenue beat, outlook 'on track'
Axogen (NASDAQ:AXGN) stock rose pre-market May 5 after the company Q1 revenue beat analysts' estimates a day ago. Q1 revenue remained largely flat Y/Y to $31M. The company said that
Seekingalpha · 05/05 12:57
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
More
No Data
Learn about the latest financial forecast of AXGN. Analyze the recent business situations of Axogen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
33.33%Buy
16.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AXGN stock price target is 18.80 with a high estimate of 25.00 and a low estimate of 14.00.
High25.00
Average18.80
Low14.00
Current 10.00
EPS
Actual
Estimate
-0.16-0.12-0.08-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 216
Institutional Holdings: 43.35M
% Owned: 103.25%
Shares Outstanding: 41.98M
TypeInstitutionsShares
Increased
54
1.88M
New
22
1.05M
Decreased
36
1.08M
Sold Out
21
1.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.36%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/President/Chief Executive Officer/Director
Karen Zaderej
Chief Financial Officer/Executive Vice President
Peter Mariani
Chief Human Resource Officer
Maria Martinez
Chief Compliance Officer/General Counsel
Brad Ottinger
Vice President - Operations
Mike Donovan
Vice President
Erick Devinney
Vice President
Mark Friedman
Other
Isabelle Billet
Other
Eric Sandberg
Other
Angelo Scopelianos
Lead Director/Independent Director
Amy Mcbride-Wendell
Independent Director
Gregory Freitag
Independent Director
Mark Gold
Independent Director
John Johnson
Independent Director
Alan Levine
Independent Director
Guido Neels
Independent Director
Paul Thomas
No Data
No Data
About AXGN
Axogen, Inc. is focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Its platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers Axotouch Two-Point Discriminator, used to measure the innervation density of any surface area of the skin. Its products are used by surgeons during surgical interventions to repair a variety of physical nerve damage or transection throughout the body, which can range from a simple laceration of a finger to a complex brachial plexus injury, as well as nerve injuries caused by dental, orthopedic, and other surgical procedures. Its portfolio of products is available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Webull offers kinds of AxoGen Inc stock information, including NASDAQ:AXGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGN stock methods without spending real money on the virtual paper trading platform.